ProcDNA appoints Utkarsh Agarwal as Director of Technology to strengthen healthcare data capabilities. October 29, 2026 Highlights. * Utkarsh Agarwal has joined ProcDNA as Director of Technology. * His experience spans ProcDNA, Innovaccer, ZS and Cognizant. * His expertise includes enterprise data platforms, data engineering, master data management and healthcare analytics. * The appointment is intended to strengthen ProcDNA's technology capabilities for healthcare and life sciences clients. ProcDNA adds technology leadership experience. ProcDNA has appointed Utkarsh Agarwal as Director of Technology, strengthening its technology leadership as the company continues to develop analytics and technology solutions for the healthcare and life sciences sectors. Agarwal brings experience in enterprise data platforms, healthcare analytics, technology consulting and AI-driven transformation. His professional background includes roles at ProcDNA, Innovaccer, ZS and Cognizant, covering data engineering, master data management, analytics, enterprise delivery and business transformation. The appointment reflects the importance of technology leadership in delivering data-intensive solutions for pharmaceutical and healthcare organisations. These businesses depend on reliable data infrastructure and analytics capabilities to support commercial decisions, operational processes and digital initiatives. ProcDNA announced the appointment as part of its effort to strengthen its technology capabilities. The company has not disclosed a new business unit, specific client engagements or financial targets associated with the leadership change. Experience across data engineering and healthcare analytics. Agarwal's career spans several areas of enterprise technology, including consulting, data engineering, master data management and analytics. His experience across different organisations provides exposure to the technical and delivery requirements involved in building and supporting enterprise data solutions. His time at Cognizant and ZS adds a consulting and enterprise-services dimension to his background, while his experience at Innovaccer connects with the healthcare technology sector. His previous association with ProcDNA also gives him familiarity with the company's business and service environment. These capabilities are relevant to organisations that need to consolidate data from multiple systems, improve data quality and make information more accessible to analytics and business teams. In healthcare and life sciences, data initiatives may involve complex relationships between commercial systems, customer information, product data and operational platforms. Master data management can help organisations maintain consistent records across these systems, while data engineering provides the pipelines and infrastructure required to make information usable. Technology leaders must also coordinate architecture, delivery teams, client requirements and implementation priorities. Agarwal's experience across these areas aligns with the broad responsibilities associated with enterprise technology leadership. Technology as an enabler of life sciences analytics. ProcDNA describes itself as an analytics and technology consulting firm focused on the life sciences industry. Its work spans areas including analytics, insights, data and technology, supporting organisations that need to translate complex information into business decisions. The sector's technology requirements extend beyond producing dashboards or analytical models. Companies also need dependable data foundations, scalable platforms and integration between systems that support commercial and operational activities. For example, pharmaceutical organisations may use analytics to understand market performance, evaluate customer engagement, improve planning and support commercial execution. The effectiveness of these initiatives depends on the quality of the underlying data and the ability to maintain consistent information across business functions. AI introduces further requirements around data availability, integration, governance and the deployment of solutions within existing workflows. While AI-driven transformation is part of Agarwal's stated expertise, ProcDNA has not announced a specific AI platform or product launch tied to his appointment. His appointment should therefore be viewed as a technology leadership development rather than evidence of a particular new offering or quantified improvement in client outcomes. Why the appointment matters for ProcDNA. As a specialist consulting firm, ProcDNA operates at the intersection of life sciences, analytics and enterprise technology. Strengthening technology leadership can help a company coordinate technical delivery with client needs and evolving requirements across the sector. A director-level technology role can involve guiding platform development, improving delivery practices, supporting client relationships and helping teams translate business problems into technical solutions. The precise scope of Agarwal's responsibilities has not been publicly detailed beyond the appointment and his broad areas of expertise. The move also comes against a backdrop of continued investment in data and AI capabilities across healthcare and pharmaceutical businesses. As organisations expand these initiatives, demand remains for technology teams that understand both enterprise systems and the context in which analytical solutions are used. For ProcDNA, the appointment adds experience across consulting, data platforms and healthcare technology. Its longer-term impact will depend on how those capabilities contribute to client delivery, service development and the company's technology roadmap. What to watch next. The next indicators will be whether ProcDNA announces additional technology initiatives, expands its data and AI offerings, or discloses new client engagements linked to its growing capabilities. For now, Agarwal's appointment represents a leadership development within ProcDNA's technology organisation. His background across healthcare analytics, data engineering and enterprise delivery aligns with the company's focus on supporting life sciences clients through analytics and technology solutions. The appointment adds to ProcDNA's wider leadership developments in 2026, including its September elevation of Rajan Dua to Executive Director to lead the AI practice. The two moves concern different leadership responsibilities and should not be interpreted as evidence of a single reorganisation without further confirmation. Together, these developments make technology and AI leadership a relevant area to monitor as ProcDNA continues to build its specialist capabilities for the life sciences market. Nishant Sharma research analyst Experienced Associate with a demonstrated history of working in the information technology and services industry.

ProcDNA named a Major Contender in Everest Group's Life Sciences AI and Analytics for Commercial PEAK. NEWS - OCT 15, 2026 ProcDNA has been recognized as a Major Contender in Everest Group's Life Sciences AI and Analytics Services for Commercial PEAK Matrix(R) Assessment 2025. Everest Group's PEAK Matrix(R) is an authoritative, multi-dimensional framework that assesses global service providers across market impact (adoption, portfolio mix, and client value) and vision and capability (innovation, domain investments, delivery footprint, and technical depth). Earning a spot as a Major Contender highlights ProcDNA's rapid rise as a trusted analytics and AI partner to global pharmaceutical and biotech organizations. By combining deep commercial acumen with cutting-edge machine learning and Generative AI, its teams help life sciences brands streamline sales force strategy, optimize omnichannel HCP engagement, and uncover actionable patient insights. This recognition validates its vision of modernizing commercial biopharma operations with agile, high-impact data solutions. ProcDNA want to thank its clients for their continued partnership and trust in tackling their most complex commercial challenges, as well as its consultants, data scientists, and engineers for their relentless commitment to analytical rigor and delivery excellence.